S&P 500   3,974.32 (-0.08%)
DOW   32,513.21 (+0.25%)
QQQ   306.46 (-0.74%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.14 (+2.35%)
BABA   96.06 (+11.54%)
AMD   93.83 (-2.88%)
T   18.88 (+0.05%)
F   11.57 (+0.43%)
MU   58.43 (-2.27%)
CGC   1.87 (-0.80%)
GE   92.86 (-0.48%)
DIS   95.47 (-0.16%)
AMC   4.65 (+2.20%)
PFE   40.17 (-0.12%)
PYPL   72.71 (-0.80%)
NFLX   327.45 (-0.06%)
S&P 500   3,974.32 (-0.08%)
DOW   32,513.21 (+0.25%)
QQQ   306.46 (-0.74%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.14 (+2.35%)
BABA   96.06 (+11.54%)
AMD   93.83 (-2.88%)
T   18.88 (+0.05%)
F   11.57 (+0.43%)
MU   58.43 (-2.27%)
CGC   1.87 (-0.80%)
GE   92.86 (-0.48%)
DIS   95.47 (-0.16%)
AMC   4.65 (+2.20%)
PFE   40.17 (-0.12%)
PYPL   72.71 (-0.80%)
NFLX   327.45 (-0.06%)
S&P 500   3,974.32 (-0.08%)
DOW   32,513.21 (+0.25%)
QQQ   306.46 (-0.74%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.14 (+2.35%)
BABA   96.06 (+11.54%)
AMD   93.83 (-2.88%)
T   18.88 (+0.05%)
F   11.57 (+0.43%)
MU   58.43 (-2.27%)
CGC   1.87 (-0.80%)
GE   92.86 (-0.48%)
DIS   95.47 (-0.16%)
AMC   4.65 (+2.20%)
PFE   40.17 (-0.12%)
PYPL   72.71 (-0.80%)
NFLX   327.45 (-0.06%)
S&P 500   3,974.32 (-0.08%)
DOW   32,513.21 (+0.25%)
QQQ   306.46 (-0.74%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.14 (+2.35%)
BABA   96.06 (+11.54%)
AMD   93.83 (-2.88%)
T   18.88 (+0.05%)
F   11.57 (+0.43%)
MU   58.43 (-2.27%)
CGC   1.87 (-0.80%)
GE   92.86 (-0.48%)
DIS   95.47 (-0.16%)
AMC   4.65 (+2.20%)
PFE   40.17 (-0.12%)
PYPL   72.71 (-0.80%)
NFLX   327.45 (-0.06%)
NASDAQ:CTMX

CytomX Therapeutics - CTMX Stock Forecast, Price & News

$1.53
-0.26 (-14.53%)
(As of 03/28/2023 11:45 AM ET)
Add
Compare
Today's Range
$1.43
$1.61
50-Day Range
$1.69
$2.84
52-Week Range
$1.17
$3.02
Volume
2.04 million shs
Average Volume
2.73 million shs
Market Capitalization
$101.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.46

CytomX Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.09 Rating Score
Upside/​Downside
109.3% Upside
$3.17 Price Target
Short Interest
Healthy
2.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
-0.01mentions of CytomX Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$30,332 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.31) to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

306th out of 1,002 stocks

Pharmaceutical Preparations Industry

133rd out of 488 stocks


CTMX stock logo

About CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Stock News Headlines

Nevada Could be the Source for America's Green Future
Industry shift towards lithium driven by green energy goals
CytomX Therapeutics Earnings Preview
Nevada Could be the Source for America's Green Future
Industry shift towards lithium driven by green energy goals
See More Headlines
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Company Calendar

Last Earnings
11/04/2021
Today
3/27/2023
Next Earnings (Confirmed)
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTMX
Employees
174
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.46
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+93.1%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

Net Income
$-83,610,000.00
Net Margins
-135.65%
Pretax Margin
-135.65%

Debt

Sales & Book Value

Annual Sales
$69.57 million
Book Value
$1.37 per share

Miscellaneous

Free Float
61,789,000
Market Cap
$118.28 million
Optionable
Optionable
Beta
0.69

Key Executives

  • Sean A. McCarthySean A. McCarthy
    Chairman, President & Chief Executive Officer
  • Chris Ogden
    Chief Financial & Accounting Officer
  • Marcia P. Belvin
    Senior Vice President & Head-Research
  • Lloyd A. Rowland
    Secretary, Chief Compliance Officer & Senior VP
  • Danielle Olander
    Senior VP-Talent & Systems Development













CTMX Stock - Frequently Asked Questions

Should I buy or sell CytomX Therapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View CTMX analyst ratings
or view top-rated stocks.

What is CytomX Therapeutics' stock price forecast for 2023?

11 brokerages have issued 1 year target prices for CytomX Therapeutics' shares. Their CTMX share price forecasts range from $1.50 to $8.00. On average, they anticipate the company's stock price to reach $3.17 in the next year. This suggests a possible upside of 109.3% from the stock's current price.
View analysts price targets for CTMX
or view top-rated stocks among Wall Street analysts.

How have CTMX shares performed in 2023?

CytomX Therapeutics' stock was trading at $1.60 at the beginning of the year. Since then, CTMX shares have decreased by 5.3% and is now trading at $1.5150.
View the best growth stocks for 2023 here
.

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,880,000 shares, an increase of 48.0% from the February 28th total of 1,270,000 shares. Based on an average daily trading volume, of 2,490,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.9% of the shares of the company are short sold.
View CytomX Therapeutics' Short Interest
.

When is CytomX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our CTMX earnings forecast
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.05. The biotechnology company earned $17.59 million during the quarter, compared to the consensus estimate of $18.53 million. CytomX Therapeutics had a negative net margin of 135.65% and a negative trailing twelve-month return on equity of 166.29%. During the same period last year, the business posted ($0.32) EPS.

What ETFs hold CytomX Therapeutics' stock?

ETFs with the largest weight of CytomX Therapeutics (NASDAQ:CTMX) stock in their portfolio include Formidable ETF (FORH).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (5.31%), Millennium Management LLC (2.60%), Renaissance Technologies LLC (2.03%), Assenagon Asset Management S.A. (1.38%), Two Sigma Investments LP (1.12%) and Platinum Investment Management Ltd. (0.96%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Jeffrey B Landau, Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends
.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $1.52.

How much money does CytomX Therapeutics make?

CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $100.11 million and generates $69.57 million in revenue each year. The biotechnology company earns $-83,610,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

The company employs 174 workers across the globe.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353.

This page (NASDAQ:CTMX) was last updated on 3/28/2023 by MarketBeat.com Staff